Kennedy Capital Management Inc. acquired a new position in shares of Clovis Oncology, Inc. (NASDAQ:CLVS) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 42,309 shares of the biopharmaceutical company’s stock, valued at approximately $3,961,000. Kennedy Capital Management Inc. owned 0.09% of Clovis Oncology at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Clovis Oncology by 71.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,819 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 758 shares during the period. Advisors Asset Management Inc. lifted its stake in shares of Clovis Oncology by 160.7% during the second quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 1,168 shares during the period. Legato Capital Management LLC acquired a new stake in shares of Clovis Oncology during the second quarter worth $220,000. Bank of Montreal Can lifted its stake in shares of Clovis Oncology by 284.9% during the second quarter. Bank of Montreal Can now owns 2,702 shares of the biopharmaceutical company’s stock worth $253,000 after buying an additional 2,000 shares during the period. Finally, PNC Financial Services Group Inc. lifted its stake in shares of Clovis Oncology by 3.7% during the first quarter. PNC Financial Services Group Inc. now owns 2,800 shares of the biopharmaceutical company’s stock worth $179,000 after buying an additional 100 shares during the period. Institutional investors and hedge funds own 98.94% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Kennedy Capital Management Inc. Acquires Shares of 42,309 Clovis Oncology, Inc. (CLVS)” was first reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://transcriptdaily.com/2017/09/17/kennedy-capital-management-inc-acquires-shares-of-42309-clovis-oncology-inc-clvs.html.
Clovis Oncology, Inc. (NASDAQ CLVS) opened at 69.46 on Friday. The stock’s market cap is $3.40 billion. Clovis Oncology, Inc. has a one year low of $25.50 and a one year high of $99.45. The company’s 50 day moving average is $74.21 and its 200 day moving average is $68.78.
Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.27) by ($0.02). The company had revenue of $14.62 million for the quarter, compared to analysts’ expectations of $13.07 million. Clovis Oncology’s revenue for the quarter was down 32.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($2.07) EPS. On average, equities research analysts expect that Clovis Oncology, Inc. will post ($7.56) EPS for the current year.
In related news, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction on Monday, July 17th. The shares were sold at an average price of $91.56, for a total transaction of $274,680.00. Following the completion of the sale, the insider now owns 197,583 shares in the company, valued at approximately $18,090,699.48. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director James C. Blair sold 18,450 shares of the stock in a transaction on Friday, August 4th. The stock was sold at an average price of $78.61, for a total transaction of $1,450,354.50. Following the sale, the director now owns 2,185 shares of the company’s stock, valued at approximately $171,762.85. The disclosure for this sale can be found here. In the last quarter, insiders have sold 24,450 shares of company stock valued at $1,935,185. 17.40% of the stock is owned by company insiders.
CLVS has been the subject of several research reports. ValuEngine upgraded shares of Clovis Oncology from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Cann reiterated a “hold” rating on shares of Clovis Oncology in a research note on Monday, July 31st. Credit Suisse Group reiterated an “outperform” rating and set a $88.00 price objective on shares of Clovis Oncology in a research note on Friday, June 16th. Zacks Investment Research upgraded shares of Clovis Oncology from a “hold” rating to a “buy” rating and set a $105.00 price objective for the company in a research note on Wednesday, July 12th. Finally, Bank of America Corporation reiterated a “buy” rating on shares of Clovis Oncology in a research note on Thursday, August 3rd. Nine investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $84.91.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology, Inc. (NASDAQ:CLVS).
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.